Metabolism of selegiline in humans: Identification, excretion, and stereochemistry of urine metabolites

Drug Metabolism and Disposition

Volumn 25, Issue 6, 1997, Pages 657-662

  Shin, Ho Sang ^a  

^a Kongju National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DRUG METABOLITE; EPHEDRINE; HYDROXYAMPHETAMINE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; NORPSEUDOEPHEDRINE; NORSELEGILINE; PHOLEDRINE; PSEUDOEPHEDRINE; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DEALKYLATION; DRUG DETERMINATION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADULT; ANTIPARKINSON AGENTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; STEREOISOMERISM;

EID: 0031010732     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. J. Knoll: The pharmacology of (-)deprenyl. J. Neurol. Transm. 22 (Suppl.),75-89 (1986).
2. W. Birkmayer, P. Reiderer, L. Ambrozi, and M. B. H. Youdim: Implications of combined treatment with "madopar' and L-deprenyl in Parkinson's disease - a long term study. Lancet 26, 439-443 (1977).
3. G. P. Reynolds, J. D. Elsworth, K. Blau, M. Sandler, A. J. Lees, and G. M. Stern: Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6, 542-544 (1978)
4. E. H. Heinonen, V. Myllyl, and K. Sotaniemi: Pharmacokinetics and metabolism of selegiline. Acta Neurol. Scand. 80 (Suppl. 126), 93-99 (1989).
5. T. Yoshida, Y. Yamada, T. Yamamoto, and Y. Kuroiwa: Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitor potency. Xenobiotica 16, 129-136 (1986).
6. H. Kalasz, L. Kerecsen, J. Knoll, and J. Pucsok: Chromatographic studies on the binding, action and metabolism of (-)-deprenyl. J. Chromatogr. 499, 589-599 (1990).
7. S. R. Philips: Amphetamine, p-hydroxyamphetamine and α-phenethylamine in mouse brain and urine after (-)- and (+)-deprenyl administration. J. Pharm. Pharmacol. 33, 739-741 (1981).
8. R. Kikura, A. Ishigami, and Y. Nakahara: Studies on comparison of metabolites in urine between deprenyl and methamphetamine. III. Enantiomeric composition analysis of metabolites in mouse urine by HPLC with GITC chiral reagent. Jpn. J. Toxicol. Environ. Health 38, 136-141 (1992).
9. S. Yasar, C. W. Schindler, E. B. Thorndike, I. Szelemyi, and S. R. Goldberg: Evaluation of the stereoisomers of deprenyl for amphetamine like discriminative stimulus effects in rats. J. Pharmacol. Exp. Ther. 265, 1-6 (1993).
10. M. Donike: N-Trifluoracetyl-O-trimethylsilylphenolalkylamine: Darstellung und massenspezifischer gaschromatographischer Nachweis. J. Chromatogr. 103, 91-112 (1974).
11. H. S. Shin and M. Donike: Stereospecific derivatization of amphetamines, phenol- and hydroxyamines, and quantification of the enantiomers by capillary GLC-MS. Anal. Chem. 68, 3015-3020 (1996).
12. E. H. Heinonen and R. Lammintausta: A review of the pharmacology of selegiline. Acta Neurol. Scand. 84 (Suppl. 136), 44-59 (1991).
13. P. Chrisp, G. J. Mammen, and E. M. Sorkin: Selegiline - a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drug Aging 1, 228-248 (1991).